Halozyme Therapeutics Inc. shares reached an all-time high of $109.59 on Wednesday, closing within pennies of the 52-week peak at $109.55. The biotech company’s stock has gained 49.33% over the past year and surged 58% in the last six months, with a year-to-date advance of 62%.
The milestone follows the release of second-quarter 2026 results that exceeded analyst expectations. Non-GAAP earnings came in at $2.28 per share, topping the $1.81 estimate. Revenue totaled $481 million, surpassing the $401.27 million forecast. The company attributed the outperformance to record royalty revenue and strong performance across several partnered drugs.
Analysts have responded with upward revisions. Citizens raised its price target to $93 from $92 while maintaining a Market Outperform rating, citing expectations for continued royalty growth. H.C. Wainwright reiterated its Buy rating with a $115 price target, pointing to positive Phase 3 trial data from partner Argenx.
